Novo Nordisk

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments.

CEO

Maziar Mike Doustdar

CEOMaziar Mike Doustdar

Employees

68,794

Employees68,794

Headquarters

Bagsværd, Capital Region

HeadquartersBagsværd, Capital Region

Founded

1923

Founded1923

Employees

68,794

Employees68,794

NVO Key Statistics

Market cap

178.86B

Market cap178.86B

Price-Earnings ratio

11.61

Price-Earnings ratio11.61

Dividend yield

3.04%

Dividend yield3.04%

Average volume

14.21M

Average volume14.21M

High today

$40.60

High today$40.60

Low today

$39.30

Low today$39.30

Open price

$40.13

Open price$40.13

Volume

5.58M

Volume5.58M

52 Week high

$81.44

52 Week high$81.44

52 Week low

$35.12

52 Week low$35.12

NVO News

Nasdaq 2h

A Monthly Weight Loss Shot? Why Pfizer Could Topple Lilly's and Novo's GLP-1 Duopoly

Key Points Novo Nordisk and Eli Lilly are largely responsible for creating today's weight-loss drug market. The two companies, however, can’t fend off creativ...

Nasdaq 22h

Here's Why Agios Pharmaceuticals Crashed 23% Today

Key Points Agios Pharmaceuticals shares dropped 23% following Novo Nordisk's trial results. Novo's etavopivat outperformed Agios' mitapavit in key sickle cell...

Investor's Business Daily 22h

Why Novo Nordisk's Surprise Win Hammered Agios Pharmaceuticals Stock

Technology Why Novo Nordisk's Surprise Win Hammered Agios Pharmaceuticals Stock Licensing Shares of Agios Pharmaceuticals (AGIO) took a header Monday after Novo...

Analyst ratings

63%

of 35 ratings

Buy

31.4%

Hold

62.9%

Sell

5.7%

More NVO News

TipRanks 22h

H.C. Wainwright cuts Agios target on smaller market post Novo data

H.C. Wainwright analyst Emily Bodnar lowered the firm’s price target on Agios Pharmaceuticals (AGIO) to $50 from $65 and keeps a Buy rating on the shares. Novo...

TipRanks 1d

Novo Nordisk Details Progress of DKK 15 Billion Share Buyback Programme

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

TipRanks 3d

Novo Nordisk’s Surprise Rebound: Value, Dividends and AI

Novo Nordisk ( (NVO) ) has risen by 7.45%. Read on to learn why. Claim 30% Off TipRanks Unlock hedge fund-level data and powerful investing tools for smarter, s...

Investor's Business Daily 4d

Eli Lilly's Pill Lags Novo Nordisk's In First Week. Why Stock Rallied.

Technology Eli Lilly's Pill Lags Novo Nordisk's In First Week. Why Stock Rallied. Licensing Eli Lilly's (LLY) oral weight-loss drug, Foundayo, nabbed 1,390 pres...

MarketWatch 4d

Lilly’s new GLP-1 pill is off to a ‘robust’ start

The early success of Eli Lilly’s new GLP-1 pill is the latest signal that Americans are still eager for pills that can help them lose weight. Foundayo was appr...

The Motley Fool 4d

Is Viking Therapeutics the Ultimate Millionaire-Maker Obesity Stock for 2026?

Pharmaceutical and biotech companies may offer your portfolio a sense of stability, and this is for one good reason: Patients need their medical treatments, so...

Simply Wall St 5d

Assessing Novo Nordisk’s Valuation After Recent Share Price Swings

Advertisement What Novo Nordisk’s Recent Performance Signals for Investors Novo Nordisk (NYSE:NVO) has drawn fresh attention after a mixed run in its share pe...

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.